Search

Displaying results 5761 - 5770 of 9132 in total
  1. Drug

    RGX-501

    go.drugbank.com/drugs/DB17639
    Investigational

    RGX-501 is an adeno-associated virus vector 8 (AAV8)-mediated gene therapy that delivers a functional copy of the human low-density lipoprotein receptor (LDLR) gene to liver cells.

  2. Drug

    Temanogrel

    go.drugbank.com/drugs/DB05227
    Investigational

    APD791 is an oral anti-thrombotic drug candidate being evaluated in a Phase 1 clinical trial by Arena.

  3. Drug

    Ranirestat

    go.drugbank.com/drugs/DB05327
    Investigational

    Ranirestat is a structurally novel and stereospecifically potent aldose reductase (AKR1B; EC 1.1.1.21) inhibitor, which contains a succinimide ring that undergoes ring-opening at physiological pH levels

  4. Drug

    J147

    go.drugbank.com/drugs/DB13957
    Experimental

    [A31606,A31607,A31608] It is a curcumin derivative and a potent neurogenic and neuroprotective drug candidate initially developed for the treatment of neurodegenerative conditions associated with aging … J147 is an experimental drug with reported effects against both Alzheimer's disease and ageing in mouse models of accelerated aging.

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  5. Drug

    Taspoglutide

    go.drugbank.com/drugs/DB14027
    Investigational

    As of May 2013 no new trials had been registered. … Taspoglutide is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche.

  6. Drug

    AZD7442

    go.drugbank.com/drugs/DB15787
    Investigational

    [L15596] It was developed by AstraZeneca with the goal of conferring at least 6 months of protection against COVID-19 - a significantly longer window of efficacy than that of other vaccines.[L15591] … AZD7442 is a combination of SARS-CoV-2 antibodies (AZD8895 + AZD1061) currently undergoing phase I clinical trials for the prevention and treatment of COVID-19.

  7. Drug

    CIGB 2020 Vaccine

    go.drugbank.com/drugs/DB15808
    Experimental

    As of July, 2020, a Randomized control clinical trial (RPCEC00000306) is underway to evaluate prophylaxis potential in suspected contacts of Covid-19 patients. … CIGB 2020 is a vaccine candidate administered nasally and sublingually, working to strengthen immunity in the areas administered.

  8. Drug

    Adlinacogene civaparvovec

    go.drugbank.com/drugs/DB16788
    Investigational

    Adlinacogene civaparvovec is an investigational _in vivo_ genome editing therapeutic product. … It uses proprietary zinc finger nuclease (ZFN) genome editing to insert into the DNA of liver cells a copy of the F9 gene, which controls the production of Factor IX.

  9. Drug

    Peginterferon alfacon-1

    go.drugbank.com/drugs/DB05860
    Experimental

    PEGylation is a technology for the chemical attachment of polyethylene glycol (PEG) polymer chains to a broad range of drug substances such as peptides and proteins including antibody fragments; small … [Infergen] is a bio-engineered type I interferon alpha that is FDA-approved for the treatment of patients with chronic hepatitis C infections.

  10. Drug

    1alpha,24S-Dihydroxyvitamin D2

    go.drugbank.com/drugs/DB06117
    Experimental

    Studies have shown LR-103 has the same potency as calcitriol, but much lower toxicity. … LR-103 is a naturally occurring D-hormone that is produced by the kidneys from vitamin D. LR-103 is one of the D-hormones produced from Hectorol.